Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 45,000 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The stock was acquired at an average price of $6.42 per share, for a total transaction of $288,900.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $19,702,665.42. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, July 20th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The shares were purchased at an average price of $6.46 per share, for a total transaction of $34,884.00.
  • On Monday, July 17th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were purchased at an average price of $6.04 per share, for a total transaction of $10,872.00.
  • On Friday, July 14th, Phillip Md Et Al Frost purchased 12,600 shares of Opko Health stock. The shares were purchased at an average price of $6.16 per share, for a total transaction of $77,616.00.
  • On Wednesday, July 12th, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The shares were purchased at an average price of $6.12 per share, for a total transaction of $22,032.00.
  • On Monday, July 10th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were purchased at an average price of $6.19 per share, for a total transaction of $309,500.00.
  • On Thursday, July 6th, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The shares were purchased at an average price of $6.29 per share, for a total transaction of $157,250.00.
  • On Monday, July 3rd, Phillip Md Et Al Frost purchased 60,800 shares of Opko Health stock. The shares were purchased at an average price of $6.44 per share, for a total transaction of $391,552.00.
  • On Friday, June 30th, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The shares were purchased at an average price of $6.58 per share, for a total transaction of $23,688.00.
  • On Wednesday, June 28th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were purchased at an average price of $6.87 per share, for a total transaction of $12,366.00.
  • On Tuesday, June 27th, Phillip Md Et Al Frost purchased 21,800 shares of Opko Health stock. The shares were purchased at an average price of $6.77 per share, for a total transaction of $147,586.00.

Shares of Opko Health, Inc. (NASDAQ:OPK) traded up 0.078% on Tuesday, reaching $6.445. 442,550 shares of the company were exchanged. The stock has a 50 day moving average price of $6.48 and a 200-day moving average price of $7.52. The stock’s market capitalization is $3.61 billion. Opko Health, Inc. has a 12 month low of $5.99 and a 12 month high of $12.15.

Opko Health (NASDAQ:OPK) last released its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.02. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The firm had revenue of $296.10 million during the quarter, compared to the consensus estimate of $313.36 million. During the same period in the prior year, the business posted ($0.02) earnings per share. Opko Health’s quarterly revenue was up 1.8% compared to the same quarter last year. On average, equities analysts expect that Opko Health, Inc. will post ($0.20) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Phillip Md Et Al Frost Acquires 45,000 Shares of Opko Health, Inc. (NASDAQ:OPK) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/25/phillip-md-et-al-frost-acquires-45000-shares-of-opko-health-inc-nasdaqopk-stock.html.

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Opko Health by 4.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company’s stock worth $210,576,000 after buying an additional 1,112,843 shares in the last quarter. BlackRock Inc. raised its stake in Opko Health by 11,481.3% in the first quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock worth $181,163,000 after buying an additional 22,449,752 shares in the last quarter. State Street Corp raised its stake in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock worth $87,412,000 after buying an additional 3,138,685 shares in the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management raised its stake in Opko Health by 62.4% in the first quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 5,061,154 shares of the biotechnology company’s stock worth $40,489,000 after buying an additional 1,944,549 shares in the last quarter. Finally, Norges Bank purchased a new stake in Opko Health during the fourth quarter worth about $30,421,000. 23.64% of the stock is owned by institutional investors.

A number of research firms have recently issued reports on OPK. Zacks Investment Research lowered shares of Opko Health from a “hold” rating to a “sell” rating in a report on Thursday, May 4th. BidaskClub upgraded shares of Opko Health from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $19.50 price target on shares of Opko Health in a report on Friday, June 16th. Jefferies Group LLC restated a “hold” rating and set a $8.00 price target on shares of Opko Health in a report on Monday, June 12th. Finally, Barrington Research boosted their price target on shares of Opko Health to $11.00 and gave the company an “outperform” rating in a report on Tuesday, July 18th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Opko Health has an average rating of “Buy” and an average target price of $14.72.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.